通过STAT1/FOXO1通路恢复血管光滑肌细胞的自,TIMP3减轻了血管化
Yu Liu1, Beidi Sun2, Jie Yang1
1Department of Cardiology, Guangxi Hospital Division of the First Affiliated Hospital, Sun Yat-sen University, Nanning, 530022, Guangxi, China.
Biochemical and biophysical research communications
|December 18, 2025
概括
组织金属蛋白酶-3抑制剂 (TIMP3) 通过增强自和抑制STAT1/FOXO1通路来减少血管化. 这一发现表明TIMP3是慢性病 (CKD) 并发症的潜在治疗标.
科学领域:
- 心血管生物学 心血管生物学
- 细胞生物学 细胞生物学
- 分子医学是分子医学.
背景情况:
- 血管化是心血管疾病的标志,涉及血管中异常矿物沉积,特别是在慢性病 (CKD) 中.
- 自是一种细胞自我降解过程,在防止血管光滑肌细胞 (VSMC) 化方面发挥着作用.
- 组织抑制金属蛋白酶-3 (TIMP3) 在血管化的具体作用和分子机制尚不清楚.
研究的目的:
- 研究TIMP3在血管化中的作用.
- 阐明TIMP3影响VSMC化和自的分子机制.
- 在CKD诱导的血管化模型中评估TIMP3的治疗潜力.
主要方法:
- 使用慢性病 (CKD) 鼠标模型和β-糖酸盐 (β-GP) 诱导的VSMCs.
- 使用von Kossa和Alizarin Red S染色评估了血管化,并量化了水平.
- 通过LC3免疫光和西部抹迹评估自流量;研究了STAT1/FOXO1信号通路.
主要成果:
- 在化动脉和VSMC中,TIMP3表达减少.
- 过度表达TIMP3减弱了化,减少了Runx2,并增强了自流.
- TIMP3抑制了STAT1的激活,并恢复了FOXO1,这表明STAT1/FOXO1通路介导了其保护作用.
- 在体内,TIMP3过度表达减少了大动脉化,并增强了CKD小鼠的自.
结论:
- TIMP3通过恢复自和通过STAT1/FOXO1通路抑制VSMC骨质变化来减轻血管化.
- 这些发现确定了TIMP3作为CKD血管化的潜在治疗标.
- TIMP3在调节自和VSMC表型中的作用为心血管病理生理学提供了新的见解.
更多相关视频
相关概念视频
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
TGF - β Signaling Pathway
10.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.4K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
The JAK-STAT Signaling Pathway
11.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.8K


